Compare SELF & GLTO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SELF | GLTO |
|---|---|---|
| Founded | 1983 | 2011 |
| Country | United States | Denmark |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 57.8M | 54.5M |
| IPO Year | N/A | 2020 |
| Metric | SELF | GLTO |
|---|---|---|
| Price | $5.03 | $25.00 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $41.00 |
| AVG Volume (30 Days) | ★ 43.8K | 30.0K |
| Earning Date | 11-07-2025 | 03-18-2026 |
| Dividend Yield | ★ 5.77% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.16 | N/A |
| Revenue | ★ $12,733,279.00 | N/A |
| Revenue This Year | $1.59 | N/A |
| Revenue Next Year | $1.62 | N/A |
| P/E Ratio | $31.38 | ★ N/A |
| Revenue Growth | ★ 3.36 | N/A |
| 52 Week Low | $4.73 | $2.01 |
| 52 Week High | $5.89 | $38.33 |
| Indicator | SELF | GLTO |
|---|---|---|
| Relative Strength Index (RSI) | 48.94 | 52.61 |
| Support Level | $4.90 | $23.85 |
| Resistance Level | $5.15 | $27.75 |
| Average True Range (ATR) | 0.08 | 2.77 |
| MACD | -0.00 | 0.01 |
| Stochastic Oscillator | 60.42 | 44.36 |
Global Self Storage Inc is a self-administered and self-managed REIT that owns, operates, manages, acquires, develops, and redevelops self-storage properties. The company's self-storage properties are designed to offer affordable, easily accessible, and secure storage space for residential and commercial customers. It has one segment of Rental operations. Through its wholly-owned subsidiaries, the company owns and/or manages close to thirteen self-storage properties in Connecticut, Illinois, Indiana, New York, Ohio, Pennsylvania, South Carolina, and Oklahoma.
Galecto Inc is a clinical-stage biotechnology company developing therapeutics designed to target the biological processes that lie at the heart of cancer and liver diseases. Its initial focus is on the development of small-molecule inhibitors of galectin-3 and lysyl oxidase-like 2, or LOXL2. Its product candidate GB0139 is for the treatment of severe fibrotic lung diseases such as idiopathic pulmonary fibrosis, or IPF, a life-threatening progressive fibrotic disease of the lung. Its product GB1211, a selective oral galectin-3 inhibitor for the treatment of fibrosis related to non-alcoholic steatohepatitis, or NASH, and GB2064, a selective oral inhibitor of LOXL2 that it initially plans to develop for the treatment of myelofibrosis.